Armatus Bio to Lead Development of CMT1A Gene Therapy

Armatus Bio to Lead Development of CMT1A Gene Therapy

314831

Armatus Bio to Lead Development of CMT1A Gene Therapy

Armatus Bio will now further develop a potential gene therapy for Charcot-Marie-Tooth disease type 1A (CMT1A), aiming to conduct clinical trials. According to a press release from the CMT Research Foundation, which has been funding this therapy’s preclinical development, Armatus is in the process of licensing the gene therapy, which will be renamed as ARM-101. The decision follows promising results from a two-year study using a mouse model of the disease. Recommended Reading November 10, 2021 News by…

You must be logged in to read/download the full post.